Search Results

Clinigen, the global pharmaceutical services company, announces the launch of NaviGATE, a UK-based pilot educational programme for rare disease patient advocates and organisations.

Clinigen Limited, the global pharmaceutical services company, has completed the divestment of four cancer supportive care products from its established brands portfolio to CNX Therapeutics, a speciality pharmaceutical company with a focus on improving access to medicines that are critical to the well-being of patients.

Clinigen Limited (‘Clinigen’) (‘the Company’), the global pharmaceutical services company, has entered into an agreement to divest Proleukin® (interleukin-2 (aldesleukin)), to Iovance Biotherapeutics, Inc.

Clinigen Limited, the global pharmaceutical services company, has agreed to acquire Drug Safety Navigator Inc., a specialist pharmacovigilance service provider based in the US.

Clinigen Limited is pleased to notethe announcement of top-line results from MIROCALS a phase 2b randomised placebo-controlled trial investigating the efficacy and safety of low dose interleukin-2 for controlling neuro-inflammation in newly-diagnosed patients with amyotrophic lateral sclerosis.

Clinigen Limited, the global pharmaceutical services company, announces it has nearly doubled its US site capacity to better service large-scale clinical trials.

Secura Bio, Inc. (Secura Bio) - (www.securabio.com), today announced that it has entered into a distribution agreement for COPIKTRA (duvelisib) with Clinigen Group Plc (Clinigen) covering 39 countries in Europe including Austria, Belgium, Croatia, Czech Republic, Denmark, Finland, France, Greece, Hungary, Ireland, Italy, The Netherlands, Poland, Portugal, Spain, Sweden and Switzerland.

Humanigen, Inc., a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm,’ announced it has entered into an arrangement with Clinigen Group plc a global pharmaceutical Services and Products company, to implement a Managed Access Program for lenzilumab.

Munich-based pharmaceutical contract development organization Adragos Pharma GmbH successfully completed the acquisition of Lamda Laboratories S.A. in Athens.

Clinigen Group plc, the global pharmaceutical and services company, has signed an exclusive agreement with Xeris Pharmaceuticals, Inc. to manage the supply and distribution of Gvoke™ injection, a treatment for diabetes, outside the US.